ES2071837T3 - Fragmento (1-37) de hpth, su preparacion, medicamentos que lo contienen y su utilizacion. - Google Patents

Fragmento (1-37) de hpth, su preparacion, medicamentos que lo contienen y su utilizacion.

Info

Publication number
ES2071837T3
ES2071837T3 ES90917747T ES90917747T ES2071837T3 ES 2071837 T3 ES2071837 T3 ES 2071837T3 ES 90917747 T ES90917747 T ES 90917747T ES 90917747 T ES90917747 T ES 90917747T ES 2071837 T3 ES2071837 T3 ES 2071837T3
Authority
ES
Spain
Prior art keywords
hpth
fragment
peptide
existence
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917747T
Other languages
English (en)
Inventor
Wolf-Georg Forssmann
Franz Herbst
Peter Schulz-Knappe
Knut Adermann
Michael Gagelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemopep Pharma GmbH
Original Assignee
Haemopep Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemopep Pharma GmbH filed Critical Haemopep Pharma GmbH
Application granted granted Critical
Publication of ES2071837T3 publication Critical patent/ES2071837T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

UN PEPTIDO DE LA SANGRE HUMANA, HPTH (1-37), CUYA ESTRUCTURA HA SIDO ESCLARECIDA, SE PUEDE UTILIZAR COMO UNA DROGA CON FINES DE DIAGNOSTICO, MEDICOS E INDUSTRIALES. EL AISLAMIENTO DE UN FRAGMENTO DE HPTH (38-64) DEMUESTRA LA EXISTENCIA DEL HPTH (1-37). LA EXTRACCION DE LOS AMINOACIDOS DE TERMINO AMINO EN EL HPTH (1-37) REDUCE SU ACTIVIDAD BIOLOGICA. EL HPTH (1-37) QUE CIRCULA EN LA SANGRE ES IDENTICO A LA SUSTANCIA DE REFERENCIA SINTETICA HPTH (1-37), PERO NO A FRAGMENTOS COMO POR EJEMPLO HPTH (1-33), HPTH (1-34) O HPTH (1-38). LA EXISTENCIA DE LA FORMA MOLECULAR DEL HPTH (1-37) SE PROBO MEDIANTE UNA ESPECTROSCOPIA EN MASA (METODO DE DESORCION DEL PLASMA). UNA ACTIVIDAD BIOLOGICA DIFERENTE Y LAS DIFERENCIAS EN LA ESTRUCTURA PEPTIDA TRIDIMENSIONAL ENTRE EL FRAGMENTO DE HPTH (1-37) Y OTROS FRAGMENTOS DE HPTH DEMUESTRA QUE ESTE FRAGMENTO DE HPTH ES EL PEPTIDO NATURAL PREFERENTE DE LA FAMILIA DE LAS PARATHORMONAS, QUE DEBERIA SER UTILIZADO PARA EL TRATAMIENTO DE ENFERMEDADES DEL PARATIROIDES ,DE LOS SISTEMAS CIRCULATORIO Y RESPIRATORIO, DE LOS ORGANOS GENITALES MASCULINOS Y DE LOS RIÑONES.
ES90917747T 1989-10-27 1990-10-25 Fragmento (1-37) de hpth, su preparacion, medicamentos que lo contienen y su utilizacion. Expired - Lifetime ES2071837T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3935738A DE3935738A1 (de) 1989-10-27 1989-10-27 Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff

Publications (1)

Publication Number Publication Date
ES2071837T3 true ES2071837T3 (es) 1995-07-01

Family

ID=6392300

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90917747T Expired - Lifetime ES2071837T3 (es) 1989-10-27 1990-10-25 Fragmento (1-37) de hpth, su preparacion, medicamentos que lo contienen y su utilizacion.

Country Status (10)

Country Link
EP (1) EP0497915B1 (es)
JP (1) JP3135122B2 (es)
AT (1) ATE121424T1 (es)
AU (1) AU643725B2 (es)
CA (1) CA2071538C (es)
DE (2) DE3935738A1 (es)
DK (1) DK0497915T3 (es)
ES (1) ES2071837T3 (es)
GR (1) GR3015909T3 (es)
WO (1) WO1991006564A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
HUT68010A (en) * 1991-12-17 1995-05-29 Procter & Gamble Pharma The use of bisphonates and parathyroid hormone for the treatment of osteoporosis
DE4203040A1 (de) * 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE4434551A1 (de) * 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptide aus der Sequenz des hPTH (1-37)
DE19517430A1 (de) * 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
CA2237296C (en) * 1995-11-16 2008-10-07 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
BR9812068A (pt) * 1997-09-09 2000-09-26 Hoffmann La Roche Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US7820393B2 (en) 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US6923968B2 (en) 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US7893021B2 (en) 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
CN105473610A (zh) * 2013-08-21 2016-04-06 卡迪拉保健有限公司 用于pth的纯化方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology

Also Published As

Publication number Publication date
JPH05505594A (ja) 1993-08-19
JP3135122B2 (ja) 2001-02-13
EP0497915A1 (de) 1992-08-12
WO1991006564A1 (de) 1991-05-16
DE3935738A1 (de) 1991-05-08
GR3015909T3 (en) 1995-07-31
DE59008949D1 (de) 1995-05-24
CA2071538A1 (en) 1991-04-28
ATE121424T1 (de) 1995-05-15
DK0497915T3 (da) 1995-09-25
CA2071538C (en) 2000-09-19
AU6871291A (en) 1991-05-31
AU643725B2 (en) 1993-11-25
EP0497915B1 (de) 1995-04-19

Similar Documents

Publication Publication Date Title
ES2071837T3 (es) Fragmento (1-37) de hpth, su preparacion, medicamentos que lo contienen y su utilizacion.
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
GB2108388A (en) Composition and method for treating alcohol and drug addicts
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
DE3587941T2 (de) Gerät zur vorläufigen reperfusionsbehandlung von herzanfallsymptomen.
ATE138575T1 (de) Verfahren zur inaktivierung von viren in mit viren verunreinigten pharmazeutischen zusammensetzungen
EA199901107A1 (ru) Системы и устройства для лечения переломов костей или больных костей с помощью расширяемых тел (варианты), стерильный набор инструментов для введения в кость (варианты)
DE3684363D1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
DE69032484T2 (de) Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
EP0526544A4 (en) Therapeutic uses of actin-binding compounds
BR9714014A (pt) Dispositivo medicinal de penso com cateter
Rouchouse et al. Acute generalized exanthematous pustular dermatitis and viral infection
GR1001065B (el) Πολυπεπτιδικα αναλογα της απολιποπρωτεινης ε,διαγνωστικα συστηματα και μεθοδοι χρησιμοποιησεως αυτων.
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
Luben Purification of a lymphokine: osteoclast activating factor from human tonsil lymphocytes
GREGERSEN Postpartum haemolytic-uraemic syndrome successfully treated with antithrombin III
JPS60258120A (ja) 胸腺製品の製造方法
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
Goldstein et al. Thymosins and anti-thymosins: properties and clinical applications
Biggs et al. Prolonged Q fever associated with inappropriate secretion of anti-diuretic hormone
ATE67672T1 (de) Protein c-inhibitor (pci) als pharmazeutikum und diagnostikum, verfahren zu herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci.
Gordan A direct action of parathyroid hormone on dead bone in vitro
ATE184287T1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
Janeway Blood and blood derivatives—A new public health field

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 497915

Country of ref document: ES